Oculis Holding Ag (OCS) - News Archive

In recent years, significant developments in ophthalmic therapeutics have been guided by innovative clinical trials and breakthroughs in drug formulation. Oculis Holding AG, a key player in the global biopharmaceutical...

Oculis Achieves Successful $100 Million Share Offering Amid Expanding Capital StrategyIn a decisive move highlighting its growing influence in the biopharmaceutical sector, Oculis Holding AG, a global leader in ophthalm...

Oculis Holding AG Expands Capital Base with New Share Issuance: A Strategic Move for Future GrowthIn a significant development for Oculis Holding AG, a global biopharmaceutical company based in Zug, Switzerland, the org...

Navigating the Shifting Landscape: Oculis Holding AG s Recent Changes in Voting Rights and Their Implications for ShareholdersZUG, Switzerland Oculis Holding AG has recently published a significant press release announc...

Oculis Holding AG recently announced promising results from its Phase 2 ACUITY trial for OCS-05, a potential first-in-class neuroprotective therapy aimed at treating acute optic neuritis. The company successfully met it...

In the dynamic world of global finance and biopharmaceutical advancements, two nations stand at the forefront - the United States and Iceland. Their respective markets have become the stage upon which significant corpor...

IntroductionOculis Holding AG, a global biopharmaceutical company dedicated to preserving vision and enhancing eye care, has announced the appointment of Dr. Sharon Klier as Chief Development Officer. Dr. Klier brings e...

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab: A Novel Precision Medicine Strategy to Transform Dry Eye Disease Treatment Groundbreaking Outcomes Could Revolutionize Dry Eye Diseas...

Zug, May 17, 2024 - Oculis Holding AG, a renowned global biopharmaceutical company, has recently announced the issuance of registered ordinary shares, significantly impacting its shareholders and showcasing its continuo...

Oculis Holding AG, a global biopharmaceutical company dedicated to saving sight and enhancing eye care, recently reported the successful enrollment completion of its Phase 2 ACUITY trial. This trial aims to evaluate the...

Oculis Holding AG, a leading biopharmaceutical company, has announced the successful closing of its registered direct offering, thus raising an impressive $59 million in financing. Simultaneously, the company has commen...

Oculis Holding AG, a leading global biopharmaceutical company dedicated to preserving sight and enhancing eye care, has announced the appointment of Dr. Snehal Shah as the President of Research & Development (R&D). With...

ConclusionOculis Holding AG s OCS-01 has demonstrated significant potential as an advanced treatment option for patients experiencing post-cataract surgery pain and inflammation. The Phase 3 OPTIMIZE-1 trial showcased p...

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership AppointmentsZUG, Switzerland, and BOSTON, Feb. 28, 2024 - Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company...